Amber Therapeutics Analysis
What is Amber Therapeutics?
First adaptive neuromodulation therapy for mixed urinary incontinence
Location
London, United Kingdom
Employees
11-50
Founded
2021
Product Features & Capabilities
- Amber-UI therapy with adaptive neuromodulation
- PicostimTM System for pudendal nerve stimulation
- Closed-loop bioelectrical therapy with real-time physiological sensing
- Fully implantable device for long-term use
Use Cases
Treat women with mixed urinary incontinence; Address both urge and stress incontinence simultaneously; Restore normal physiological function in refractory cases; Enable dynamic adaptation between stimulation modes; Support clinical trials in women with severe refractory urge incontinence
Other Considerations
Closed-loop adaptive therapy for mixed incontinence; First-in-human AURA-2 study with 13 patients; $100M Series A financing in 2024; Acquired Bioinduction Ltd's Picostim DyNeuMo platform in 2023; Led by Oxford Science Enterprises, NEA, F-Prime Capital, Lightstone Ventures, and 8VC; Partnerships with University Hospital Antwerp for clinical trials
